FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City Feb 5, 2019 10:35AM
Tapimmune, Inc. (TPIV) Reports $11M DoD Grant to Mayo Clinic to Fund Phase 2 Study of TPIV110 for HER2/neu-Targeted Breast Cancer Vaccine Oct 10, 2018 06:35AM
TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant Oct 10, 2018 06:30AM
TapImmune to Present at Two Upcoming Investor Conferences Sep 25, 2018 08:05AM
TapImmune To Present at 2018 Janney Healthcare Conference Sep 12, 2018 08:05AM


Aug 29, 2018 06:30AM TapImmune to Participate at Two Upcoming Industry Conferences
Jun 8, 2018 09:18AM Tapimmune, Inc. (TPIV) Prices 17.5M Share Private Placement at $4/Share, to Issue 13.13M Warrants
Jun 8, 2018 09:15AM TapImmune Announces Pricing of $70 Million Private Placement
May 31, 2018 06:30AM TapImmune to Present at the Jefferies 2018 Global Healthcare Conference
May 30, 2018 06:30AM TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum
May 23, 2018 06:30AM TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform
May 22, 2018 06:30AM TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
May 16, 2018 06:30AM TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
May 16, 2018 06:30AM TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
May 15, 2018 04:05PM TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
May 15, 2018 05:32AM TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
May 7, 2018 06:30AM TapImmune to Present at 2018 NYC Oncology Investor Conference
May 1, 2018 06:30AM TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference
Apr 5, 2018 04:05PM TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update
Mar 29, 2018 06:30AM TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast
Mar 28, 2018 06:30AM TapImmune to Present at The MicroCap Conference
Mar 15, 2018 08:00AM TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
Mar 14, 2018 06:30AM TapImmune to Present at Two Upcoming Investor Conferences
Feb 6, 2018 06:30AM TapImmune to Participate in Two Upcoming Investor Conferences
Jan 3, 2018 06:30AM TapImmune to Present at Biotech Showcase™ 2018
Dec 12, 2017 06:38AM Tapimmune, Inc. (TPIV) Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating TNBC
Dec 12, 2017 06:30AM TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
Dec 6, 2017 06:30AM TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer
Nov 21, 2017 06:30AM TapImmune to Present at 29th Annual Piper Jaffray Healthcare Conference
Nov 17, 2017 04:05PM TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast
Nov 15, 2017 04:05PM TapImmune Provides Third Quarter 2017 Corporate and Clinical Update
Nov 14, 2017 06:36AM Tapimmune, Inc. (TPIV) Reports Completion of Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study
Nov 14, 2017 06:30AM TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
Nov 13, 2017 04:35PM TapImmune to Provide Third Quarter 2017 Business Update Conference Call and Webcast
Oct 18, 2017 06:41AM Tapimmune, Inc. (TPIV) CEO Announces Letter to Shareholders
Oct 18, 2017 06:30AM A Personal Letter to the Shareholders from TapImmune's New Chief Executive Officer
Oct 12, 2017 06:30AM TapImmune to Present at the 2017 BioFlorida Conference
Sep 25, 2017 06:32AM Tapimmune, Inc. (TPIV) Names Peter Hoang as President & CEO
Sep 25, 2017 06:30AM TapImmune Appoints Peter Hoang as President and Chief Executive Officer
Aug 31, 2017 04:05PM TapImmune Provides Second Quarter 2017 Corporate and Clinical Update
Aug 29, 2017 08:30AM TapImmune to Provide Second Quarter 2017 Business Update Conference Call and Webcast
Aug 8, 2017 08:05AM Tapimmune, Inc. (TPIV) Amends Phase 2 Trial of TPIV200 to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer
Aug 8, 2017 08:00AM TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments
Jul 18, 2017 09:15AM TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology
Sep 6, 2016 09:00AM MicroCap Review Magazine Fall 2016 Issue Now Available
Sep 6, 2016 09:00AM MicroCap Review Magazine Fall 2016 Issue Now Available
Mar 17, 2016 08:30AM StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.